What Had To Hold Up For OptimizeRx (OPRX) And What Broke First?
OptimizeRx has just rolled out CopayCue, a new tool that plugs savings offers into prescribing software using real-time intent data from over 400 electronic health record and e-prescribing platforms. For OptimizeRx shareholders, the loss over the past year was 54.3%, including dividends. That decline frames a simple question. If you had bought on 2 October 2025, what did this kind of product launch and the later drop in revenue and net margin really imply about the business you were backing?
OptimizeRx is not the only name tied to this theme. Zero in on 35 healthcare AI stocks and compare how each one is priced.
The Two Stories Investors Had To Choose Between On OptimizeRx
The shares cost US$17.6 at the start of the period, and anyone looking at OptimizeRx then was really choosing between two very different futures for its digital pharma platform.
On the optimistic side, the upbeat Narrative pointed to a Fair Value of US$19, a notional target price if its assumptions played out, based on revenue growing 8.0% a year and profit margin eventually reaching 4.2%.
The more cautious view anchored on a Fair Value of US$11 and treated tighter data privacy rules as the key risk. It assumed 7.2% annual revenue growth and profit margin eventually matching an 8.8% industry level with a lower 23.3x future P/E.
What The Results Changed For OptimizeRx
CopayCue gave the optimistic OptimizeRx story a tangible product tied directly to the prescribing moment, yet the harder numbers pulled in another direction. Revenue went from US$29.195m in Q2 2025 to US$20.504m in Q2 2026, while net income swung from a US$1.532m profit to a US$0.703m loss and net margin moved from 5.2% to a loss-making 3.4%. Overall, the evidence supported the cautious case.
The key assumption that got tested was profitable scale. For a different stock, you would check whether new launches show up in revenue and net margin together, rather than treating product news as a shortcut to durable earnings.
What OptimizeRx’s Drop Leaves You Paying For Today
OptimizeRx now trades at US$8.57, with the selected Narrative’s Fair Value sitting above that level based on its own assumptions about workflow data, omnichannel tools and execution through 2027.
That view leans on contracted demand and cost control, so a buyer today would need confidence that recent revenue momentum and margin discipline really can offset regulatory and client concentration risks.
"Sequential improvement in gross margin to 63.8%, supported by scale and favorable product/channel mix, and disciplined cost management resulting in flat operating expenses despite significant revenue growth, are leading to operating leverage and improving net margins that could contribute to sustained profitability and shareholder returns."
One Narrative disagrees with today's price. → See where this Narrative says OptimizeRx should trade
Before The Next Story Makes Headlines
The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.
- Company 1 - 42% below our estimate - uses device trade-ins to feed refurbishment and expand resale inventory.
- Company 2 - 25% below our estimate - develops gene-based treatments beyond cystic fibrosis, including kidney-focused therapies.
- Company 3 - 23% below our estimate - integrates acquired storage, inverter and software assets into one project platform.
Three companies from the same screener. Open all 31 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com